Thursday, Sep 28, 2023
English News
  • Hyderabad
  • Telangana
  • AP News
  • India
  • World
  • Entertainment
  • Science and Tech
  • Sport
  • Business
  • Rewind
  • ...
    • NRI
    • View Point
    • cartoon
    • Columns
    • Education Today
    • Reviews
    • Property
    • Videos
    • Lifestyle
E-Paper
  • NRI
  • View Point
  • cartoon
  • Columns
  • Reviews
  • Education Today
  • Property
  • Videos
  • Lifestyle
Home | Business | Hyderabad Based Optimus Applies For Molnupiravir Eua With Dcgi

Hyderabad-based Optimus applies for molnupiravir EUA with DCGI

Hyderabad: Optimus, which has completed molnupiravir oral capsule phase 3 clinical trial, has applied for emergency use authorization (EUA) for the drug with the Drugs Controller General of India (DCGI).    On May 18, 2021, the Hyderabad-based company received approval from the DCGI to conduct the phase 3 trial as per the recommendations of the […]

By Telangana Today
Updated On - 08:10 PM, Thu - 28 October 21
Hyderabad-based Optimus applies for molnupiravir EUA with DCGI
Hyderabad-based Optimus was the first company to apply for phase 3 trial.
whatsapp facebook twitter telegram

Hyderabad: Optimus, which has completed molnupiravir oral capsule phase 3 clinical trial, has applied for emergency use authorization (EUA) for the drug with the Drugs Controller General of India (DCGI).   

On May 18, 2021, the Hyderabad-based company received approval from the DCGI to conduct the phase 3 trial as per the recommendations of the subject expert committee (SEC) of the CDSCO, DGHS, Ministry of Health and Family Welfare.

The pharmaceutical company was the first to file for the phase 3 clinical trial of molnupiravir with the central licensing authority. The clinical trial partner of Optimus, JSS Research was tasked with the execution of the trial. The trial was conducted in 29 study sites across India to prove the superiority of molnupiravir over the standard treatment options as well as its efficacy.  

Dr D Srinivas Reddy, CMD, Optimus Pharma said, the company aims to develop a cutting-edge and affordable treatment option for Covid-19 and neutralise the disease in minimum treatment duration.

The phase 3 trial data of Optimus showed on the fifth day of the study that 78.4 per cent of the patients in the treatment group were recorded RT-PCR negative as compared to 48.2 per cent in the placebo group. On the 10th day of the study, 91.5 per cent of the patients in the treatment group were recorded RT-PCR negative as compared to 43 per cent in the placebo group.

“These results are not only a new hope to neutralise Covid-19 but also reinforce our belief in the central licensing authority of India to ensure a fair and legitimate trial and provide the necessary support for a self-reliant pharmaceutical industry,” he added.


Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .


Telangana Today Whatsapp
  • Follow Us :
  • Tags
  • Drugs Controller General of India
  • Emergency Use Authorization
  • Optimus

Related News

  • Tesla Optimus Humanoid Robot – Latest Updates

    Tesla Optimus Humanoid Robot – Latest Updates

  • Biological E reduces Corbevax price to Rs 250 per dose

    Biological E reduces Corbevax price to Rs 250 per dose

  • DCGI grants approval to single-shot Sputnik Light for emergency use: Dr Reddy’s

    DCGI grants approval to single-shot Sputnik Light for emergency use: Dr Reddy’s

  • Optimus receives tentative nod from FDA for generic Brexpiprazole tablets

    Optimus receives tentative nod from FDA for generic Brexpiprazole tablets

  • Optimus interim phase 3 data for Molnupiravir shows 78.3% efficacy

    Optimus interim phase 3 data for Molnupiravir shows 78.3% efficacy

  • Hetero’s phase 3 trial results of Molnupiravir shows fewer hospital admissions

    Hetero’s phase 3 trial results of Molnupiravir shows fewer hospital admissions

Latest News

  • Opinion: Drive SDGs from grassroots

    39 mins ago
  • Jaishankar meets US NSA Sullivan, discusses progress in bilateral ties

    46 mins ago
  • AP Deputy CM inaugurates regional prohibition, excise laboratory worth Rs 2.5 cr

    51 mins ago
  • Vasundhara faction leader Devi Singh Bhati joins BJP again

    52 mins ago
  • Editorial: Architect of Green Revolution

    52 mins ago
  • Indian Navy wins Inter Services Athletics tournament first time in 72 years

    58 mins ago
  • Disha Patani pens adorable birthday note for her best friend Mouni Roy

    1 hour ago
  • Zero tolerance policy against drug smugglers: Punjab AAP reacts to arrest of Congress MLA

    1 hour ago

company

  • Home
  • About Us
  • Contact Us

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

© Copyrights 2022 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam